Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Propanc Biopharma (Nasdaq: PPCB) has received a certificate of grant from the USPTO for its "proenzyme composition" patent, marking its fourth US patent. The patent specifically covers a future clinical dose of PRP, the company's lead asset targeting metastatic cancer treatment.
The company's IP portfolio now includes 90 patents filed in major jurisdictions. PRP is targeting the global metastatic cancer treatment market, projected to reach $111.2 billion by 2027. The treatment works by inducing cell differentiation rather than directly killing cancer cells, offering a relatively non-toxic approach to treating metastatic cancer from solid tumors.
Propanc plans to commence a Phase 1B First-In-Human study next year and is pursuing capital raising initiatives, including a digital asset diversification strategy.
Propanc Biopharma (Nasdaq: PPCB) ha ottenuto un certificato di concessione dall'USPTO per il suo brevetto sulla proenzyme composition, segnando il suo quarto brevetto statunitense. Il brevetto riguarda specificamente una dose clinica futura di PRP, l'asset principale dell'azienda destinato al trattamento del cancro metastatico.
Il portafoglio IP dell'azienda comprende ora 90 brevetti depositati nelle principali giurisdizioni. PRP punta al mercato globale del trattamento del cancro metastatico, previsto raggiungere $111,2 miliardi entro il 2027. Il trattamento agisce inducendo la differenziazione cellulare invece di uccidere direttamente le cellule tumorali, offrendo un approccio relativamente poco tossico al trattamento del cancro metastatico proveniente da tumori solidi.
Propanc prevede di avviare uno studio Phase 1B First-In-Human il prossimo anno e sta conducendo iniziative di raccolta capitale, inclusa una strategia di diversificazione degli asset digitali.
Propanc Biopharma (Nasdaq: PPCB) ha recibido un certificado de concesión por parte de la USPTO para su patente de proenzyme composition, marcando su cuarto patente en EE. UU.. La patente cubre específicamente una dosis clínica futura de PRP, el principal activo de la empresa enfocado al tratamiento del cáncer metastásico.
El portafolio de propiedad intelectual de la empresa ya incluye 90 patentes registradas en las principales jurisdicciones. PRP apunta al mercado global de tratamiento del cáncer metastásico, que se proyecta alcanzar $111,2 mil millones para 2027. El tratamiento funciona induciendo la diferenciación celular en lugar de matar directamente las células cancerosas, ofreciendo un enfoque relativamente poco tóxico para tratar el cáncer metastásico proviente de tumores sólidos.
Propanc planea iniciar un estudio Phase 1B First-In-Human el próximo año y está llevando a cabo iniciativas de captación de capital, incluida una estrategia de diversificación de activos digitales.
Propanc Biopharma (Nasdaq: PPCB)가 USPTO로부터 proenzyme composition 특허에 대한 허가를 받았으며, 이는 미국에서의 네 번째 특허를 의미합니다. 이 특허는 향후 임상에서의 PRP 용량을 구체적으로 다루며, 전이성 암 치료를 목표로 하는 회사의 주요 자산입니다.
회사의 지적재산 포트폴리오는 현재 90개의 특허를 주요 관할 구역에 출원했습니다. PRP는 전이성 암 치료 시장을 겨냥하며, 2027년까지 1112억 달러에 이를 것으로 예상됩니다. 이 치료법은 암세포를 직접 죽이기보다 세포 분화(유세포 분화)를 유도하는 방식으로 작동하여 고형종양에서 발현되는 전이성 암 치료에 비교적 독성이 적은 접근법을 제공합니다.
Propanc는 내년에 Phase 1B First-In-Human 연구를 시작할 계획이며, 디지털 자산 다각화 전략을 포함한 자본 조달 이니셔티브를 추진하고 있습니다.
Propanc Biopharma (NYSE: PPCB) a reçu un certificat d'octroi de l'USPTO pour son brevet sur la proenzyme composition, marquant son quatrième brevet américain. Le brevet couvre spécifiquement une dose clinique future de PRP, l'actif principal de l'entreprise visant le traitement du cancer métastatique.
Le portefeuille IP de l'entreprise comprend désormais 90 brevets déposés dans les principales juridictions. PRP vise le marché mondial du traitement du cancer métastatique, qui devrait atteindre 111,2 milliards de dollars d'ici 2027. Le traitement agit en induisant la différenciation cellulaire plutôt que de tuer directement les cellules cancéreuses, offrant une approche relativement peu toxique pour traiter le cancer métastatique provenant de tumeurs solides.
Propanc prévoit de lancer une étude Phase 1B First-In-Human l'année prochaine et poursuit des initiatives de levée de capitaux, y compris une stratégie de diversification des actifs numériques.
Propanc Biopharma (Nasdaq: PPCB) hat von der USPTO eine Bestätigung für das Patent zur proenzyme composition erhalten, was sein viertes US-Patent bedeutet. Das Patent deckt ausdrücklich eine zukünftige klinische Dosis von PRP ab, dem führenden Asset des Unternehmens zur Behandlung metastasierender Krebsarten.
Das IP-Portfolio des Unternehmens umfasst nun 90 Patente, die in den wichtigsten Rechtsordnungen angemeldet sind. PRP zielt auf den globalen Markt für die Behandlung metastasierenden Krebs ab und soll voraussichtlich bis 2027 111,2 Milliarden USD erreichen. Die Behandlung wirkt, indem sie die Differenzierung von Zellen fördert statt Krebszellen direkt abzutöten, und bietet damit einen relativ ungiftigen Ansatz zur Behandlung metastasierender Krebsarten aus soliden Tumoren.
Propanc plant im nächsten Jahr eine Phase-1B First-In-Human-Studie zu beginnen und führt Kapitalbeschaffungsinitiativen durch, einschließlich einer Digital-Asset-D Diversifikationsstrategie.
Propanc Biopharma (بورصة ناسداك: PPCB) قد حصلت على شهادة منح من USPTO لبراءة اختراعها الخاصة بـproenzyme composition، مما يمثل رابع براءة اختراع أمريكية للشركة. تغطي البراءة جرعة سريرية مستقبلية من PRP، وهو الأصول الرئيسي للشركة الموجه لعلاج السرطان النِقّلِي.
المجموعة الملكية الفكرية للشركة تتضمن الآن 90 براءة اختراع مُقدمة في ولايات قضائية رئيسية. تستهدف PRP سوق علاج السرطان النِقْلي العالمي، المتوقع أن يصل إلى 111.2 مليار دولار بحلول 2027. العلاج يعمل على تحفيز تمايز الخلايا بدلاً من قتل الخلايا السرطانية مباشرة، وهو نهج غير سام نسبيًا لعلاج السرطان النِقْلي الناتج عن أورام صلبة.
تخطط Propanc لبدء دراسة Phase 1B First-In-Human في العام المقبل وتتابع مبادرات جمع رأس المال، بما في ذلك استراتيجية لتنويع الأصول الرقمية.
Propanc Biopharma（纳斯达克：PPCB） 已从美国专利商标局（USPTO）获得其“proenzyme composition”专利的授予证书，标志着公司在美国的< b>第四项专利。该专利专门覆盖未来的临床剂量PRP，作为公司面向转移性癌症治疗的核心资产。
公司的知识产权组合现在包括< b>90项专利，在主要司法辖区均已申请。PRP瞄准全球转移性癌症治疗市场，预计至2027年将达到< b>1112亿美元。该治疗通过诱导细胞分化而非直接杀死癌细胞来发挥作用，提供一种对治疗来自实体瘤的转移性癌症相对低毒性的途径。
Propanc计划在明年启动< b>Phase 1B First-In-Human 研究，并正在推进资本筹集计划，包括数字资产多元化策略。
- Fourth US patent granted, strengthening intellectual property protection
- Patent portfolio expanded to 90 patents across major jurisdictions
- PRP targets $111.2B metastatic cancer treatment market by 2027
- Treatment offers relatively non-toxic approach compared to standard therapies
- Company needs to raise additional capital for clinical trials
- Phase 1B trials yet to commence, indicating early development stage
Insights
Propanc secures critical US patent for PRP cancer treatment, strengthening IP protection ahead of Phase 1B clinical trials.
Propanc's latest patent grant from the USPTO represents a significant milestone in their intellectual property strategy. This fourth US patent specifically protects the clinical dosing formulation of their lead candidate PRP, creating a crucial barrier to competition as they advance toward human trials.
The strategic value of this patent cannot be overstated. By securing protection for the specific proenzyme composition that will be used in clinical applications, Propanc has effectively safeguarded the commercial potential of PRP across the entire treatment pathway. The global reach of this patent protection - now spanning the US, Europe, Japan, and Southeast Asia - aligns perfectly with their target market of metastatic cancer treatments, projected at $111.2 billion by 2027.
What's particularly notable is how this patent fits into Propanc's broader intellectual property mosaic of 90 patents filed globally. This comprehensive approach creates multiple layers of protection around their novel mechanism of action as an "EMT modulator" - inducing cancer cell differentiation rather than direct cytotoxicity. This patent specifically addresses the pharmaceutical composition itself, complementing their existing patents on methods of use and manufacturing processes.
The timing of this patent grant is particularly advantageous as Propanc approaches their Phase 1B First-In-Human study planned for next year. With patent protection now secured in major commercial markets, Propanc has significantly enhanced their potential licensing or partnership value while creating a clear path for market exclusivity should PRP demonstrate clinical efficacy.
Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRP
MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s “proenzyme composition” patent was received from the US Patent & Trademark Office (USPTO). The patent specifically captures a future clinical dose of the Company’s lead asset, PRP. This is the fourth US patent granted in this key strategic jurisdiction. Currently, the Company’s intellectual property portfolio consists of 90 patents filed in major jurisdictions relating to the use of PRP against solid tumors.
The proenzymes composition patent is an important part of the IP portfolio covering a possible future clinical dose of PRP, as the Company advances to a Phase 1B, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors. The patent has also been granted in other major jurisdictions such as Europe, Japan and throughout Southeast Asia. PRP is targeting the global metastatic cancer treatment market, projected to be worth US
“We continue to grow our intellectual property portfolio in the United States, which is our most important jurisdiction,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Our lead asset, PRP, is an exciting method to prevent and treat metastatic cancer from solid tumors without the severe, or even serious side effects often associated with standard therapies. PRP is relatively non-toxic because it does not kill cancer cells directly but induces cell differentiation so that they become less malignant and die off naturally. This unique phenomenon is specific to PRP, which acts as an ‘EMT (epithelial to mesenechymal transition) modulator’, enforcing the cancer cells to behave more as a normalized cell so that it is no longer a threat. We are pushing towards the commencement of the Phase 1B study next year. We are also pursuing every avenue for raising sufficient capital and employing a digital asset diversification strategy to ensure optimal cash flow as we advance PRP towards important clinical milestones.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What patent did Propanc Biopharma (PPCB) receive from the USPTO?
How does Propanc's PRP treatment work against cancer?
How many patents does Propanc Biopharma have in its portfolio?
What is the market potential for Propanc's metastatic cancer treatment?
When will Propanc begin its Phase 1B clinical trials for PRP?
